Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

NCT00882973 is registered in ClinicalTrials.gov with Samyang Biopharmaceuticals Corporation as lead sponsor.

NCT NCT00882973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00882973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer
Lead sponsor
Samyang Biopharmaceuticals Corporation
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2008
Completion date
November 30, 2010
Enrollment
18 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer